A Phase 3 interventional study of PF-06651600 and Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine in Alopecia Areata, sponsored by Pfizer. Completed at 144 sites in 17 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Alopecia Areata by Pfizer — 4 open to participants now, 8 under way, 4 of them phase 3. Alopecia Areata · Pfizer.
Among the 17 studies in Alopecia Areata by Pfizer, this one has the largest enrollment of the 10 interventional ones that give a count, is the only one that started in 2019, is one of 5 in phase 3, and was the 3rd registered.
220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.
Browse Alopecia Areata studies →4 of the 17 studies in Alopecia Areata by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada, China and 2 more countries
Ages 12+
Pfizer · Sites in United States, China, Czechia and 6 more countries
Ages 6–14
Pfizer · Sites in Korea, Republic of
Ages 12+
Pfizer · Sites in United States, Canada, China and 8 more countries
Ages 12+
By country, each count listing its studies:
Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 6
First in 2016; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,057 is above the median of 50 across 171 interventional studies indexed under Alopecia Areata.
Median enrollment 175 across the 10 interventional studies, 375 across the 6 observational. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
2 of the studies in Alopecia Areata by Pfizer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07029711Phase 3PfizerA Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | 2026-12-02 |
| NCT07821216PfizerReal-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data | 2026-11-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Alopecia Areata by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. Eligible patients from the prior studies B7931005 (NCT02974868) and B7981015 (NCT03732807) will have an opportunity to enroll as well as patients who have not previously participated in either of these studies. The study is open-label and all patients entering the study will receive active study drug.
A sub-study of approximately 60 adult patients who are participating in the B7981032 study will be conducted at select sites in the US, Australia and Canada. The sub-study will evaluate the immune response to tetanus and meningococcal vaccines in patients who have received a minimum of 6 months of 50 mg PF-06651600.
Inclusion Criteria-
For de novo participants and participants from Study B7931005 and B7981015 with >30 days between first visit in B7981032 and last dose in the prior study:
Exclusion Criteria-
For de novo participants and participants from Study B7931005 and B7981015 with >30 days between first visit in B7981032 and last dose in the prior study:
Exclusion criteria for all participants:
- Participants who have previously taken Janus kinase (JAK) inhibitors other than PF-06651600 must have received the last dose >12 weeks prior to the screening visit
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who did not previously receive study intervention in either study B7931005 or B7981015 will receive 200 milligrams (mg) PF-06651600, given as four 50 mg tablets once daily (QD) for 1 month, followed by 50 mg PF-06651600 tablet or capsule given QD for 59 months. Patients participating in the vaccine sub-study will receive the 2 vaccines or one of the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 9 visit and prior to or on the Month 56 visit of the main B7981032 study.
Drug: PF-06651600 · Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine · Biological: Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
Participants who previously received study intervention in either study B7931005 or B7981015 will receive 50 mg PF-06651600 tablet or capsule given QD for 59 months. Patients participating in the vaccine sub-study will receive the 2 vaccines or 1 of the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 6 visit and prior to or on the Month 56 visit of the main B7981032 study.
Drug: PF-06651600 · Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine · Biological: Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
50 mg oral tablets/capsules
Single intramuscular injection administered to patients participating in the vaccine sub-study
Single intramuscular injection administered to patients participating in the vaccine sub-study
Main Study: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Until Follow-up Visit
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered treatment emergent if the event had start date on or after the first dosing date of this study.
Time frame: From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)
Main Study: Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation Until Follow-up Visit
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect; other important medical events. AEs leading to discontinuation included participants who had an AE record that indicated that the AE caused the participant to be discontinued from the study or that action taken with study treatment was drug withdrawn.
Time frame: From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)
Main Study: Number of Participants According to Categorization of Vital Signs Data Until Follow-up Visit
Vital signs including blood pressure included systolic blood pressure (SBP) \[Millimeters of mercury, mmHg\]) and diastolic blood pressure (DBP) and pulse rate \[beats per minute (bpm)\] were measured using an automated device in a sitting position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Criteria for vital sign abnormalities included: SBP\<90mmHg, DBP\<50 mmHg and pulse rate\<40mmHg.
Time frame: From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)
Main Study: Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values Until Follow-up Visit
Criteria for laboratory abnormalities included:Hemoglobin, Hematocrit, Erythrocytes (\<0.8\*LLN); Ery. Volume, Hemoglobin,Mean Corpuscular HGB Concentration \<0.8\*LLN or \>1.5\*LLN;Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Neutrophils, Basophils, Eosinophils, Monocytes (\>1.2\*ULN), Prothrombin Time(\>1.1\*ULN).Clinical Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin (1.5\*ULN), Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase (\>3.0\*ULN); Albumin, Urate (\<0.8\*LLN and \>1.2\*ULN; Urea Nitrogen,Creatinine Cholesterol \>1.3\*ULN; Cholesterol \<0.8\*LLN or \>1.2\*LLN, Triglycerides,Potassium,Calcium \< 0.9x LLN \& \> 1.1x ULN; Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite \>=1; Leukocyte Erythrocytes, Leukocytes \>=20; Epithelial Cells\>=6, Hyaline Cast\>1; Bacteria\>20. Number of participants with any laboratory abnormality meeting specified criteria is included.
Time frame: From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)
Vaccine Sub-study: Percentage of Participants With Tetanus Booster Response
Booster response to tetanus toxoid was defined as: \>=4-fold rise in anti-tetanus toxoid immunoglobulin G (IgG) antibody concentration at Month 1 if the pre-vaccination concentration was \<=2.7 International Units per milliliter (IU/mL); OR \>=2-fold rise in anti-tetanus toxoid IgG antibody concentration if the pre-vaccination concentration was \>2.7 IU/mL. Two-sided 95% confidence interval (CI) was based on Clopper-Pearson exact method.
Time frame: Month 1
Main Study: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Until End of Study
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered treatment emergent if the event had start date on or after the first dosing date of this study.
Time frame: From start of study intervention (Day 1) until end of study
Main Study: Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation Until End of Study
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect; other important medical events. AEs leading to discontinuation included participants who had an AE record that indicated that the AE caused the participant to be discontinued from the study or that action taken with study treatment was drug withdrawn.
Time frame: From start of study intervention (Day 1) until end of study
Main Study: Number of Participants With Clinically Significant Abnormalities in Vital Signs Until End of Study
Vital signs including blood pressure (systolic and diastolic blood pressure \[Millimeters of mercury, mmHg\]) and pulse rate (beats per minute \[bpm\]) were measured using an automated device in a sitting position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Clinically significant abnormalities will be determined by investigator.
Time frame: From start of study intervention (Day 1) until end of study
Main Study: Number of Participants With Clinically Significant Laboratory Abnormalities Until End of Study
Following laboratory parameters were assessed: Hemoglobin, Hematocrit, Erythrocytes Erythrocyte (ery.) corpuscular volume, Ery. Mean Corpuscular hemoglobin concentration, Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Basophils, Eosinophils, Monocytes, Prothrombin Time, Bilirubin, Direct Bilirubin, Indirect Bilirubin, Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase; Albumin, Urate; Urea Nitrogen, Creatinine, Cholesterol, Triglycerides, Potassium, Calcium, Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite, Leukocyte Erythrocytes, Leukocytes; Epithelial Cells, Hyaline Cast, Bacteria. Clinically significant abnormalities will be determined by investigator.
Time frame: From start of study intervention (Day 1) until end of study
Main Study: Percentage of Participants Achieving Response Based on Severity of Alopecia Tool (SALT) Overall Score <=10 at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
SALT is a quantitative assessment of AA severity based on the scalp terminal hair loss. A visual aid was utilized showing the division of the scalp hair into four quadrants (back, top of scalp, right side and left side), with each of the four quadrants given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of the scalp in that area. SALT score is the sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. The SALT overall score included any hair loss regardless of etiology (e.g., including scalp hair loss due to both androgenetic alopecia and AA). In this outcome measure, percentage of participants with SALT overall score \<= 10 were reported. 95% CI was calculated based on normal approximation.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Main Study: Percentage of Participants Achieving Response Based on Alopecia Areata (AA) SALT Score <=10 at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. Scalp hair was divided into four quadrants (back, top of scalp, right side and left side), with each given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score=sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. SALT AA Score = SALT overall score minus SALT AGA score, where SALT overall score included any hair loss regardless of etiology and SALT AGA score included scalp hair loss only due to androgenetic alopecia. SALT AA score ranged from 0 (no hair loss) to 100 (complete scalp hair loss), with lower score indicating less hair loss. 95% CI was calculated based on normal approximation.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Main Study: Percentage of Participants Achieving Response Based on SALT Overall Score <= 20 at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
SALT is a quantitative assessment of AA severity based on the scalp terminal hair loss. A visual aid was utilized showing the division of the scalp hair into four quadrants (back, top of scalp, right side and left side), with each of the four quadrants given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of the scalp in that area. SALT score is the sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. The SALT overall score included any hair loss regardless of etiology (e.g., including scalp hair loss due to both androgenetic alopecia and AA). In this outcome measure, percentage of participants with SALT overall score \<=20 were reported. 95% CI was calculated based on normal approximation.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Main Study: Percentage of Participants Achieving Response Based on AA SALT Score <=20 at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. Scalp hair was divided into four quadrants (back, top of scalp, right side and left side), with each given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score=sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. SALT AA Score = SALT overall score minus SALT AGA score, where SALT overall score included any hair loss regardless of etiology and SALT AGA score included scalp hair loss only due to androgenetic alopecia. SALT AA score ranged from 0 (no hair loss) to 100 (complete scalp hair loss), with lower score indicating less hair loss. 95% CI was calculated based on normal approximation.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Main Study: Change From Baseline in SALT Overall Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
SALT is a quantitative assessment of AA severity based on the scalp terminal hair loss. A visual aid was utilized showing division of scalp hair into four quadrants (back, top of scalp, right side and left side), with each of four quadrants given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score is sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. SALT overall score included any hair loss regardless of etiology (e.g., including scalp hair loss due to both androgenetic alopecia and AA). For roll-over participants originating from Study B7931005 or B7981015, baseline is day 1 from Study B7931005 or B7981015. For de novo participants, baseline is day 1 from Study B7981032.
Time frame: Baseline, At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Main Study: Change From Baseline in AA SALT Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
SALT=quantitative assessment of AA severity based on scalp terminal hair loss. Scalp hair was divided into 4 quadrants (back, top of scalp, right side and left side), with each given an accurate determination of percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score=sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss). SALT AA Score = SALT overall score minus SALT AGA score, where SALT overall score included any hair loss regardless of etiology and SALT AGA score included scalp hair loss only due to androgenetic alopecia. SALT AA score ranged from 0 (no hair loss) to 100 (complete scalp hair loss), lower score= less hair loss. Baseline (Roll-over participants: Day 1 from Study B7931005 or B7981015; De novo participants: Day 1 from Study B7981032).
Time frame: Baseline, At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Main Study: Percentage of Participants Achieving Atleast 75% Improvement in Overall SALT Score From Baseline at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
SALT is a quantitative assessment of AA severity based on the scalp terminal hair loss. A visual aid was utilized showing the division of the scalp hair into four quadrants (back, top of scalp, right side and left side), with each of the four quadrants given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of the scalp in that area. SALT score is the sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. The SALT overall score included any hair loss regardless of etiology (e.g., including scalp hair loss due to both androgenetic alopecia and AA). An Overall SALT 75 response was a 75% or greater reduction from baseline in SALT score.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Main Study: Percentage of Participants Achieving Atleast 75% Improvement in AA SALT Score From Baseline at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
SALT=quantitative assessment of AA severity based on scalp terminal hair loss. Scalp hair was divided into four quadrants (back, top of scalp, right side and left side), with each given an accurate determination of percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score=sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. SALT AA Score= SALT overall score minus SALT AGA score, where SALT overall score included any hair loss regardless of etiology and SALT AGA score included scalp hair loss only due to androgenetic alopecia. SALT AA score ranged from 0 (no hair loss) to 100 (complete scalp hair loss), where lower score=less hair loss. SALT 75 response= 75% or greater reduction from baseline in AA SALT score.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Main Study: Percentage of Participants Achieving Atleast 2-Grade Improvement From Baseline or Absolute Score of 3 in the Eyebrow Assessment (EBA) at Months 1, 3, 6, 12, 18, 24 and 36 in Participants Without Normal EBA Score at Baseline
EBA is a numeric rating scale developed to characterize eyebrow hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where 0= no eyebrow, 1=minimal eyebrow, 2=moderate eyebrow and 3= normal eyebrow. Higher scores represent lesser loss of eyebrow hair. 95% CI was based on normal approximation.
Time frame: At Months 1, 3, 6, 12, 18, 24 and 36
Main Study: Percentage of Participants Achieving Atleast 2-Grade Improvement From Baseline or Absolute Score of 3 in the Eyelash Assessment (ELA) at Months 1, 3, 6, 12, 18, 24 and 36 in Participants Without Normal ELA Score at Baseline
ELA is a numeric rating scale developed to characterize eyelash hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where 0=no eyelash, 1=minimal eyelash, 2=moderate eyelash and 3=normal eyelash. Higher scores represent lesser loss of eyelash hair.
Time frame: At Months 1, 3, 6, 12, 18, 24 and 36
Main Study: Percentage of Participants Achieving Patient's Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Months 1, 3, 6, 9, 12, 18, 24 and 36
PGI-C is a self-administered single item questionnaire to evaluate the improvement or worsening of participant's AA as compared to the start of the study. Participants were required to select their response on a 7-point scale ranging from 1 (greatly worsened), 2=moderately worsened, 3=slightly worsened, 4=not changed, 5= slightly improved, 6=moderately improved, 7 (greatly improved). 95% CI was based on normal approximation.
Time frame: At Months 1, 3, 6, 9, 12, 18, 24 and 36
Main Study: Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Months 1, 3, 6, 9, 12, 18, 24 and 36: Emotional Symptoms and Activity Limitations
AAPPO scale is a 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over past week. Items 5-8 assessed emotional symptoms with responses scored from 0 ='never' to 4='always'. Items 9-11 assessed activity limitations with responses scored from 0='not at all' to 4='completely'. AAPPO emotional symptoms sub score was calculated as mean of items 5-8 and ranged from 0 (never) to 4 (always), where higher scores indicated more emotional symptoms. AAPPO activity limitations sub score was calculated as mean of items 9-11 and ranged from 0(not at all) to 4(completely), where higher scores indicated more activity limitations. For roll-over participants originating from Study B7931005 or B7981015, baseline is day 1 from Study B7931005 or B7981015. For de novo participants, baseline is day 1 from Study B7981032.
Time frame: Baseline, At Months 1, 3, 6, 9, 12, 18, 24 and 36
Main Study: Percentage of Participants With Response Based on Hair Loss Improvement From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Months 1, 3, 6, 9, 12, 18, 24 and 36, Among Participants With Score >=2 at Baseline
AAPPO scale is a 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over past week. Items 1-4 assessed current hair loss from the scalp, eyebrows, eyelashes and body using a 5 point scale that ranged from 0 ='no hair loss' and 4='complete hair loss'. In this outcome measure, percentage of participants with AAPPO domain scores of 0 = no hair loss or 1 = a little hair loss, among participants with score \>=2 at baseline are reported.
Time frame: Baseline, At Months 1, 3, 6, 9, 12, 18, 24 and 36
Main Study: Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Months 1, 3, 6, 9, 12, 18, 24 and 36
HADS is a validated 14-item questionnaire used to assess states of anxiety and depression over the past week. The HADS consisted of 2 subscales, one for anxiety (HADS-A) and one for depression (HADS-D). The depression subscale comprised of 7 items with score ranging from 0 (no presence of depression) to 3 (severe feeling of depression). Total depression subscale score was calculated as the sum of 7 items and ranged from 0 to 21; higher score indicating greater severity of depression symptoms. For roll-over participants originating from Study B7931005 or B7981015, baseline is day 1 from Study B7931005 or B7981015. For de novo participants, baseline is day 1 from Study B7981032.
Time frame: Baseline, At Months 1, 3, 6, 9, 12, 18, 24 and 36
Main Study: Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Months 1, 3, 6, 9, 12, 18, 24 and 36
HADS is a validated 14-item questionnaire used to assess states of anxiety and depression over the past week. The HADS consisted of 2 subscales, one for anxiety (HADS-A) and one for depression (HADS-D). The anxiety subscale comprised of 7 items with score ranging from 0 (no anxiety) to 3 (severe anxiety). Total anxiety subscale score was calculated as the sum of 7 items and ranged from 0 to 21; higher score indicating greater severity of anxiety symptoms. For roll-over participants originating from Study B7931005 or B7981015, baseline is day 1 from Study B7931005 or B7981015. For de novo participants, baseline is day 1 from Study B7981032.
Time frame: Baseline, At Months 1, 3, 6, 9, 12, 18, 24 and 36
Main Study: Percentage of Participants With Improvement on HADS Depression Score at Months 1, 3, 6, 9, 12, 18, 24 and 36
HADS is a validated 14-item questionnaire used to assess states of anxiety and depression over the past week. The HADS consisted of 2 subscales, one for anxiety (HADS-A) and one for depression (HADS-D). The depression subscale comprised of 7 items with score ranging from 0 (no presence of depression) to 3 (severe feeling of depression). Total depression subscale score was calculated as the sum of 7 items and ranged from 0 to 21; higher score indicating greater severity of depression symptoms. Improvement on HADS depression score was considered as achieving a "normal" depression subscale score indicative of an absence of depression. Among adults, a HADS-D score of 0-7 was considered "normal"; for adolescents, a HADS-D score of 0-6 was considered "normal". 95% CI was calculated based on normal approximation.
Time frame: At Months 1, 3, 6, 9, 12, 18, 24 and 36
Main Study: Percentage of Participants With Improvement on HADS Anxiety Score At Months 1, 3, 6, 9, 12, 18, 24 and 36
HADS is a validated 14-item questionnaire used to assess states of anxiety and depression over the past week. The HADS consisted of 2 subscales, one for anxiety (HADS-A) and one for depression (HADS-D). The anxiety subscale comprised of 7 items with score ranging from 0 (no anxiety) to 3 (severe anxiety). Total anxiety subscale score was calculated as the sum of 7 items and ranged from 0 to 21; higher score indicating greater severity of anxiety symptoms. Improvement on HADS anxiety score was considered as achieving a "normal" anxiety subscale score indicative of an absence of anxiety. Among adults, a HADS-A score of 0-7 was considered "normal"; for adolescents, a HADS-A score of 0-8 was considered "normal". 95% CI was calculated based on normal approximation.
Time frame: At Months 1, 3, 6, 9, 12, 18, 24 and 36
Vaccine Sub-study: Percentage of Participants With Anti-tetanus Antibody Level >=1.0 International Units Per Milliliter (IU/mL) at Month 1-Tdap Vaccination
Percentage of participants with anti-tetanus antibody level \>=1.0 IU/mL at Month 1 were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.
Time frame: Month 1
Vaccine Sub-study: Percentage of Participants With Anti-tetanus Antibody Level >=0.1 IU/mL at Month 1-Tdap Vaccination
Percentage of participants with anti-tetanus antibody level \>=0.1 IU/mL at Month 1 were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.
Time frame: Month 1
Vaccine Sub-study: Percentage of Participants With >=4 Times Increase in Anti-tetanus Antibody Level From Baseline at Month 1-Tdap Vaccination
Percentage of participants with \>=4 times increase in anti-tetanus antibody level from baseline were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.
Time frame: Month 1
Vaccine Sub-study: Geometric Mean Fold Change in Anti-tetanus Levels Above Baseline Values at Month 1-Tdap Vaccination
Geometric mean and 95% CI were calculated by exponentiating the mean logarithm of the observed data and the corresponding CIs. Fold change was defined as the ratio of the post-baseline result to the baseline result. The assay results below the LLOQ were set to 0.5 \* LLOQ except when pre-vaccination assay results is \< LLOQ while postvaccination result is \>= LLOQ, in which case the pre-vaccination value will be set to LLOQ.
Time frame: From Baseline (pre-vaccination on Day 1) to Month 1
Vaccine Sub-study: Geometric Mean Concentrations (GMCs) of Anti-tetanus Antibody Levels at Month 1-Tdap Vaccination
Geometric mean and 95% CI were calculated by exponentiating the mean logarithm of the observed data and the corresponding CIs. Assay results below the LLOQ were set to 0.5\* LLOQ.
Time frame: Month 1
Vaccine Sub-study: Percentage of Participants With Human Serum Bactericidal Activity (hSBA) Titer >=1:8 at Month 1 Post-vaccination for Serogroup C-Meningococcal ACWY Vaccination
Percentage of participants with hSBA titer \>=1.8 at 1 month post vaccination for serogroup C were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.
Time frame: Month 1
Vaccine Sub-study: Percentage of Participants With hSBA Titer >=1:4 at Month 1 Post-vaccination for Serogroup C-Meningococcal ACWY Vaccination
Percentage of participants with hSBA titer \>=1.4 at 1 month post vaccination for serogroup C were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.
Time frame: Month 1
Vaccine Sub-study: Geometric Mean Titers (GMT) of Antibodies for Serogroup C at Baseline and Month 1-Meningococcal ACWY Vaccination
Geometric mean and 95% CI were calculated by exponentiating the mean logarithm of the observed data and the corresponding CIs. Assay results below the LLOQ were set to 0.5\* LLOQ.
Time frame: Baseline (pre-vaccination on Day 1) and Month 1
Vaccine Sub-study: Number of Participants With SAEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect; other important medical events.
Time frame: From day of vaccination (Day 1) up to 35 days post last dose of vaccine (up to Day 36)
Vaccine Sub-study: Number of Participants With AEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: From day of vaccination (Day 1) up to 35 days post last dose of vaccine (up to Day 36)
Vaccine Sub-study: Number of Participants With AEs Leading to Discontinuation
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs leading to discontinuation included participants who had an AE record that indicated that the AE caused the participant to be discontinued from the study or that action taken with study treatment was drug withdrawn.
Time frame: From day of vaccination (Day 1) up to 35 days post last dose of vaccine (up to Day 36)
| Milestone | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | Vaccine Sub-study: Tdap With or Without Meningococcal ACWY Vaccine |
|---|---|---|---|
| Started | 449 | 603 | 0 |
| Treated | 447 | 603 | 0 |
| Completed | 289 | 332 | 0 |
| Not completed | 160 | 271 | 0 |
| Withdrew: Adverse event | 26 | 36 | 0 |
| Withdrew: Death | 1 | 1 | 0 |
| Withdrew: Lack of efficacy | 27 | 79 | 0 |
| Withdrew: Lost to follow-up | 22 | 17 | 0 |
| Withdrew: Non-compliance with study drug | 4 | 1 | 0 |
| Withdrew: Physician decision | 3 | 0 | 0 |
| Withdrew: Pregnancy | 8 | 8 | 0 |
| Withdrew: Withdrawal by subject | 41 | 57 | 0 |
| Withdrew: No longer met eligibility criteria (for adolescents) | 14 | 29 | 0 |
| Withdrew: No longer met eligibility criteria (for adults) | 4 | 2 | 0 |
| Withdrew: Other | 10 | 4 | 0 |
| Withdrew: Approved drug available for indication | 0 | 37 | 0 |
| Milestone | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | Vaccine Sub-study: Tdap With or Without Meningococcal ACWY Vaccine |
|---|---|---|---|
| Started | 289 | 332 | 0 |
| Completed | 0 | 0 | 0 |
| Not completed | 289 | 332 | 0 |
| Withdrew: Adverse event | 2 | 2 | 0 |
| Withdrew: Lack of efficacy | 7 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 |
| Withdrew: Protocol violation | 3 | 1 | 0 |
| Withdrew: Withdrawal by subject | 8 | 7 | 0 |
| Withdrew: Other | 2 | 3 | 0 |
| Withdrew: Approved drug available for indication | 179 | 222 | 0 |
| Withdrew: Ongoing | 86 | 96 | 0 |
| Milestone | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | Vaccine Sub-study: Tdap With or Without Meningococcal ACWY Vaccine |
|---|---|---|---|
| Started | 29 | 43 | 0 |
| Completed | 1 | 1 | 0 |
| Not completed | 28 | 42 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 10 | 14 | 0 |
| Withdrew: Other | 8 | 16 | 0 |
| Withdrew: Approved drug available for indication | 6 | 9 | 0 |
| Withdrew: Ongoing | 2 | 1 | 0 |
| Milestone | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | Vaccine Sub-study: Tdap With or Without Meningococcal ACWY Vaccine |
|---|---|---|---|
| Started | 0 | 0 | 17 |
| Tdap vaccination with or without acwy vaccination | 0 | 0 | 17 |
| Acwy vaccination with tdap vaccination | 0 | 0 | 13 |
| Completed | 0 | 0 | 16 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered treatment emergent if the event had start date on or after the first dosing date of this study.
| Participants | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) |
|---|---|---|
| Main Study: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Until Follow-up Visit | 401 | 515 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect; other important medical events. AEs leading to discontinuation included participants who had an AE record that indicated that the AE caused the participant to be discontinued from the study or that action taken with study treatment was drug withdrawn.
| Participants | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) |
|---|---|---|
| SAEs | 30 | 42 |
| AEs Leading to Discontinuation | 36 | 46 |
Vital signs including blood pressure included systolic blood pressure (SBP) \[Millimeters of mercury, mmHg\]) and diastolic blood pressure (DBP) and pulse rate \[beats per minute (bpm)\] were measured using an automated device in a sitting position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Criteria for vital sign abnormalities included: SBP\<90mmHg, DBP\<50 mmHg and pulse rate\<40mmHg.
| Participants | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) |
|---|---|---|
| Diastolic blood pressure (mmHg): value <50 | 11 | 15 |
| Diastolic blood pressure (mmHg): change >=20 increase | 39 | 70 |
| Diastolic blood pressure (mmHg): change >=20 decrease | 45 | 51 |
| Pulse rate (bpm): Value <40 | 1 | 3 |
| Pulse rate (bpm): Value >120 | 0 | 1 |
| Systolic blood pressure (mmHg): Value <90 | 13 | 30 |
| Systolic blood pressure (mmHg): change>=30 increase | 18 | 42 |
| Systolic blood pressure (mmHg): change>=30 decrease | 22 | 30 |
Criteria for laboratory abnormalities included:Hemoglobin, Hematocrit, Erythrocytes (\<0.8\*LLN); Ery. Volume, Hemoglobin,Mean Corpuscular HGB Concentration \<0.8\*LLN or \>1.5\*LLN;Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Neutrophils, Basophils, Eosinophils, Monocytes (\>1.2\*ULN), Prothrombin Time(\>1.1\*ULN).Clinical Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin (1.5\*ULN), Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase (\>3.0\*ULN); Albumin, Urate (\<0.8\*LLN and \>1.2\*ULN; Urea Nitrogen,Creatinine Cholesterol \>1.3\*ULN; Cholesterol \<0.8\*LLN or \>1.2\*LLN, Triglycerides,Potassium,Calcium \< 0.9x LLN \& \> 1.1x ULN; Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite \>=1; Leukocyte Erythrocytes, Leukocytes \>=20; Epithelial Cells\>=6, Hyaline Cast\>1; Bacteria\>20. Number of participants with any laboratory abnormality meeting specified criteria is included.
| Participants | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) |
|---|---|---|
| Main Study: Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values Until Follow-up Visit | 390 | 490 |
Booster response to tetanus toxoid was defined as: \>=4-fold rise in anti-tetanus toxoid immunoglobulin G (IgG) antibody concentration at Month 1 if the pre-vaccination concentration was \<=2.7 International Units per milliliter (IU/mL); OR \>=2-fold rise in anti-tetanus toxoid IgG antibody concentration if the pre-vaccination concentration was \>2.7 IU/mL. Two-sided 95% confidence interval (CI) was based on Clopper-Pearson exact method.
| Percentage of participants | Vaccine Sub-study: Tdap Vaccination |
|---|---|
| Vaccine Sub-study: Percentage of Participants With Tetanus Booster Response | 62.5 (35.4 to 84.8) |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered treatment emergent if the event had start date on or after the first dosing date of this study.
Results for this outcome have not been posted.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect; other important medical events. AEs leading to discontinuation included participants who had an AE record that indicated that the AE caused the participant to be discontinued from the study or that action taken with study treatment was drug withdrawn.
Results for this outcome have not been posted.
Vital signs including blood pressure (systolic and diastolic blood pressure \[Millimeters of mercury, mmHg\]) and pulse rate (beats per minute \[bpm\]) were measured using an automated device in a sitting position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Clinically significant abnormalities will be determined by investigator.
Results for this outcome have not been posted.
Following laboratory parameters were assessed: Hemoglobin, Hematocrit, Erythrocytes Erythrocyte (ery.) corpuscular volume, Ery. Mean Corpuscular hemoglobin concentration, Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Basophils, Eosinophils, Monocytes, Prothrombin Time, Bilirubin, Direct Bilirubin, Indirect Bilirubin, Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase; Albumin, Urate; Urea Nitrogen, Creatinine, Cholesterol, Triglycerides, Potassium, Calcium, Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite, Leukocyte Erythrocytes, Leukocytes; Epithelial Cells, Hyaline Cast, Bacteria. Clinically significant abnormalities will be determined by investigator.
Results for this outcome have not been posted.
SALT is a quantitative assessment of AA severity based on the scalp terminal hair loss. A visual aid was utilized showing the division of the scalp hair into four quadrants (back, top of scalp, right side and left side), with each of the four quadrants given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of the scalp in that area. SALT score is the sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. The SALT overall score included any hair loss regardless of etiology (e.g., including scalp hair loss due to both androgenetic alopecia and AA). In this outcome measure, percentage of participants with SALT overall score \<= 10 were reported. 95% CI was calculated based on normal approximation.
| Percentage of participants | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) |
|---|---|---|
| Month 1 | 0.9 (0.02 to 1.80) | 27.9 (24.23 to 31.50) |
| Month 3 | 16.3 (12.79 to 19.83) | 32.6 (28.77 to 36.40) |
| Month 6 | 37.7 (33.07 to 42.35) | 39.1 (35.01 to 43.22) |
| Month 9 | 49.0 (44.08 to 53.91) | 44.7 (40.39 to 49.02) |
| Month 12 | 55.8 (50.88 to 60.80) | 48.2 (43.72 to 52.70) |
| Month 15 | 59.5 (54.50 to 64.53) | 52.9 (48.28 to 57.52) |
| Month 18 | 62.3 (57.27 to 67.31) | 53.4 (48.76 to 58.12) |
| Month 21 | 62.9 (57.80 to 68.00) | 54.9 (50.18 to 59.59) |
| Month 24 | 66.4 (61.32 to 71.42) | 56.4 (51.69 to 61.17) |
| Month 28 | 68.3 (63.23 to 73.44) | 59.3 (54.51 to 64.02) |
| Month 32 | 69.9 (64.79 to 75.02) | 61.0 (56.16 to 65.76) |
| Month 36 | 70.9 (65.77 to 76.12) | 61.7 (56.73 to 66.60) |
SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. Scalp hair was divided into four quadrants (back, top of scalp, right side and left side), with each given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score=sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. SALT AA Score = SALT overall score minus SALT AGA score, where SALT overall score included any hair loss regardless of etiology and SALT AGA score included scalp hair loss only due to androgenetic alopecia. SALT AA score ranged from 0 (no hair loss) to 100 (complete scalp hair loss), with lower score indicating less hair loss. 95% CI was calculated based on normal approximation.
| Percentage of participants | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) |
|---|---|---|
| Month 1 | 1.0 (0.03 to 2.02) | 28.5 (24.68 to 32.35) |
| Month 3 | 17.7 (13.88 to 21.57) | 33.5 (29.52 to 37.52) |
| Month 6 | 39.6 (34.65 to 44.60) | 39.8 (35.56 to 44.05) |
| Month 9 | 50.7 (45.52 to 55.87) | 45.3 (40.90 to 49.78) |
| Month 12 | 56.8 (51.56 to 61.98) | 49.3 (44.74 to 53.94) |
| Month 15 | 61.4 (56.16 to 66.60) | 53.9 (49.23 to 58.64) |
| Month 18 | 65.0 (59.81 to 70.09) | 54.1 (49.38 to 58.86) |
| Month 21 | 65.2 (60.05 to 70.41) | 55.1 (50.37 to 59.89) |
| Month 24 | 67.6 (62.47 to 72.75) | 57.2 (52.39 to 61.96) |
| Month 28 | 69.2 (64.00 to 74.36) | 59.6 (54.76 to 64.35) |
| Month 32 | 70.3 (65.16 to 75.50) | 61.6 (56.82 to 66.46) |
| Month 36 | 71.1 (65.91 to 76.27) | 62.1 (57.17 to 67.03) |
SALT is a quantitative assessment of AA severity based on the scalp terminal hair loss. A visual aid was utilized showing the division of the scalp hair into four quadrants (back, top of scalp, right side and left side), with each of the four quadrants given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of the scalp in that area. SALT score is the sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. The SALT overall score included any hair loss regardless of etiology (e.g., including scalp hair loss due to both androgenetic alopecia and AA). In this outcome measure, percentage of participants with SALT overall score \<=20 were reported. 95% CI was calculated based on normal approximation.
| Percentage of Participants | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) |
|---|---|---|
| Month 1 | 2.5 (1.05 to 3.98) | 35.6 (31.68 to 39.43) |
| Month 3 | 27.7 (23.40 to 31.92) | 40.2 (36.18 to 44.16) |
| Month 6 | 50.1 (45.33 to 54.91) | 50.4 (46.16 to 54.58) |
| Month 9 | 59.5 (54.73 to 64.37) | 55.9 (51.57 to 60.19) |
| Month 12 | 65.5 (60.70 to 70.20) | 60.0 (55.59 to 64.41) |
| Month 15 | 70.7 (66.00 to 75.30) | 62.3 (57.79 to 66.77) |
| Month 18 | 71.8 (67.13 to 76.45) | 63.5 (59.01 to 68.05) |
| Month 21 | 72.8 (68.06 to 77.45) | 66.3 (61.81 to 70.75) |
| Month 24 | 73.5 (68.79 to 78.23) | 66.7 (62.16 to 71.18) |
| Month 28 | 76.8 (72.17 to 81.43) | 69.0 (64.55 to 73.50) |
| Month 32 | 78.0 (73.37 to 82.61) | 69.5 (64.99 to 74.05) |
| Month 36 | 79.1 (74.42 to 83.69) | 69.7 (65.04 to 74.37) |
SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. Scalp hair was divided into four quadrants (back, top of scalp, right side and left side), with each given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score=sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. SALT AA Score = SALT overall score minus SALT AGA score, where SALT overall score included any hair loss regardless of etiology and SALT AGA score included scalp hair loss only due to androgenetic alopecia. SALT AA score ranged from 0 (no hair loss) to 100 (complete scalp hair loss), with lower score indicating less hair loss. 95% CI was calculated based on normal approximation.
| Percentage of Participants | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) |
|---|---|---|
| Month 1 | 2.6 (0.99 to 4.11) | 36.6 (32.50 to 40.67) |
| Month 3 | 27.8 (23.26 to 32.29) | 41.2 (37.02 to 45.37) |
| Month 6 | 51.2 (46.13 to 56.30) | 51.0 (46.64 to 55.32) |
| Month 9 | 60.4 (55.39 to 65.50) | 56.5 (52.10 to 60.94) |
| Month 12 | 66.0 (61.01 to 70.98) | 61.2 (56.75 to 65.72) |
| Month 15 | 72.2 (67.35 to 76.96) | 63.4 (58.88 to 67.97) |
| Month 18 | 74.0 (69.29 to 78.74) | 64.5 (59.92 to 69.02) |
| Month 21 | 74.2 (69.39 to 78.91) | 66.6 (62.07 to 71.10) |
| Month 24 | 74.8 (70.07 to 79.61) | 66.9 (62.36 to 71.46) |
| Month 28 | 77.7 (73.03 to 82.38) | 69.2 (64.72 to 73.74) |
| Month 32 | 78.7 (74.03 to 83.30) | 69.3 (64.74 to 73.88) |
| Month 36 | 79.3 (74.62 to 83.89) | 69.9 (65.23 to 74.55) |
SALT is a quantitative assessment of AA severity based on the scalp terminal hair loss. A visual aid was utilized showing division of scalp hair into four quadrants (back, top of scalp, right side and left side), with each of four quadrants given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score is sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. SALT overall score included any hair loss regardless of etiology (e.g., including scalp hair loss due to both androgenetic alopecia and AA). For roll-over participants originating from Study B7931005 or B7981015, baseline is day 1 from Study B7931005 or B7981015. For de novo participants, baseline is day 1 from Study B7981032.
| Units on a scale | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) |
|---|---|---|
| Month 1 | -2.8 ± 9.94 | -41.8 ± 37.34 |
| Month 3 | -23.6 ± 26.51 | -46.0 ± 37.32 |
| Month 6 | -36.6 ± 32.07 | -52.0 ± 37.26 |
| Month 9 | -44.2 ± 32.71 | -56.8 ± 35.89 |
| Month 12 | -47.5 ± 32.34 | -60.1 ± 35.17 |
| Month 15 | -50.6 ± 31.89 | -62.8 ± 33.88 |
| Month 18 | -52.5 ± 31.98 | -64.2 ± 33.64 |
| Month 21 | -53.3 ± 31.70 | -65.8 ± 32.43 |
| Month 24 | -53.6 ± 31.79 | -65.5 ± 32.67 |
| Month 28 | -54.8 ± 31.81 | -67.2 ± 32.49 |
| Month 32 | -55.8 ± 31.48 | -67.8 ± 32.42 |
| Month 36 | -56.6 ± 31.99 | -68.1 ± 32.17 |
SALT=quantitative assessment of AA severity based on scalp terminal hair loss. Scalp hair was divided into 4 quadrants (back, top of scalp, right side and left side), with each given an accurate determination of percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score=sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss). SALT AA Score = SALT overall score minus SALT AGA score, where SALT overall score included any hair loss regardless of etiology and SALT AGA score included scalp hair loss only due to androgenetic alopecia. SALT AA score ranged from 0 (no hair loss) to 100 (complete scalp hair loss), lower score= less hair loss. Baseline (Roll-over participants: Day 1 from Study B7931005 or B7981015; De novo participants: Day 1 from Study B7981032).
| Units on a scale | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) |
|---|---|---|
| Month 1 | -2.9 ± 10.32 | -42.8 ± 37.48 |
| Month 3 | -23.8 ± 26.88 | -47.0 ± 37.33 |
| Month 6 | -37.3 ± 32.12 | -52.8 ± 37.05 |
| Month 9 | -44.8 ± 32.73 | -57.4 ± 35.81 |
| Month 12 | -48.5 ± 32.20 | -61.1 ± 34.82 |
| Month 15 | -51.6 ± 31.43 | -63.8 ± 33.41 |
| Month 18 | -53.5 ± 31.39 | -65.0 ± 33.16 |
| Month 21 | -53.8 ± 31.57 | -66.0 ± 32.43 |
| Month 24 | -54.1 ± 31.93 | -65.9 ± 32.62 |
| Month 28 | -55.2 ± 32.01 | -67.4 ± 32.53 |
| Month 32 | -56.0 ± 31.69 | -67.8 ± 32.55 |
| Month 36 | -56.5 ± 32.04 | -68.2 ± 32.18 |
SALT is a quantitative assessment of AA severity based on the scalp terminal hair loss. A visual aid was utilized showing the division of the scalp hair into four quadrants (back, top of scalp, right side and left side), with each of the four quadrants given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of the scalp in that area. SALT score is the sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. The SALT overall score included any hair loss regardless of etiology (e.g., including scalp hair loss due to both androgenetic alopecia and AA). An Overall SALT 75 response was a 75% or greater reduction from baseline in SALT score.
| Percentage of participants | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) |
|---|---|---|
| Month 1 | 0.9 (0.02 to 1.80) | 37.4 (33.51 to 41.36) |
| Month 3 | 21.5 (17.60 to 25.43) | 42.6 (38.56 to 46.61) |
| Month 6 | 44.2 (39.40 to 48.91) | 51.3 (47.08 to 55.50) |
| Month 9 | 55.5 (50.65 to 60.41) | 56.9 (52.56 to 61.16) |
| Month 12 | 61.8 (56.97 to 66.67) | 61.3 (56.88 to 65.64) |
| Month 15 | 67.4 (62.60 to 72.18) | 64.7 (60.31 to 69.16) |
| Month 18 | 68.4 (63.62 to 73.25) | 66.7 (62.32 to 71.17) |
| Month 21 | 69.3 (64.41 to 74.14) | 67.9 (63.49 to 72.32) |
| Month 24 | 69.9 (65.04 to 74.84) | 68.1 (63.64 to 72.55) |
| Month 28 | 73.4 (68.50 to 78.21) | 70.2 (65.82 to 74.67) |
| Month 32 | 76.4 (71.64 to 81.11) | 70.5 (66.04 to 75.01) |
| Month 36 | 76.7 (71.87 to 81.51) | 70.8 (66.16 to 75.39) |
SALT=quantitative assessment of AA severity based on scalp terminal hair loss. Scalp hair was divided into four quadrants (back, top of scalp, right side and left side), with each given an accurate determination of percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score=sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. SALT AA Score= SALT overall score minus SALT AGA score, where SALT overall score included any hair loss regardless of etiology and SALT AGA score included scalp hair loss only due to androgenetic alopecia. SALT AA score ranged from 0 (no hair loss) to 100 (complete scalp hair loss), where lower score=less hair loss. SALT 75 response= 75% or greater reduction from baseline in AA SALT score.
| Percentage of participants | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) |
|---|---|---|
| Month 1 | 1.0 (0.03 to 2.02) | 38.6 (34.52 to 42.78) |
| Month 3 | 22.8 (18.53 to 26.98) | 43.6 (39.43 to 47.84) |
| Month 6 | 45.6 (40.48 to 50.62) | 51.8 (47.43 to 56.10) |
| Month 9 | 57.1 (51.98 to 62.22) | 57.3 (52.94 to 61.76) |
| Month 12 | 62.8 (57.74 to 67.91) | 62.3 (57.88 to 66.79) |
| Month 15 | 69.2 (64.21 to 74.11) | 65.5 (61.03 to 69.99) |
| Month 18 | 70.7 (65.79 to 75.60) | 67.5 (63.08 to 71.98) |
| Month 21 | 70.8 (65.82 to 75.71) | 68.0 (63.55 to 72.48) |
| Month 24 | 72.0 (67.08 to 76.95) | 68.4 (63.87 to 72.87) |
| Month 28 | 74.8 (69.88 to 79.63) | 70.5 (66.02 to 74.93) |
| Month 32 | 77.3 (72.60 to 82.07) | 70.3 (65.80 to 74.86) |
| Month 36 | 77.2 (72.42 to 82.01) | 70.9 (66.27 to 75.51) |
EBA is a numeric rating scale developed to characterize eyebrow hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where 0= no eyebrow, 1=minimal eyebrow, 2=moderate eyebrow and 3= normal eyebrow. Higher scores represent lesser loss of eyebrow hair. 95% CI was based on normal approximation.
| Percentage of participants | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) |
|---|---|---|
| Month 1 | 4.3 (2.11 to 6.53) | 38.8 (34.45 to 43.15) |
| Month 3 | 22.3 (17.69 to 26.90) | 43.4 (38.91 to 47.83) |
| Month 6 | 37.6 (32.24 to 43.00) | 50.0 (45.36 to 54.64) |
| Month 12 | 55.0 (49.17 to 60.83) | 60.3 (55.44 to 65.18) |
| Month 18 | 59.5 (53.55 to 65.39) | 64.2 (59.28 to 69.21) |
| Month 24 | 61.2 (55.12 to 67.33) | 67.9 (62.99 to 72.87) |
| Month 36 | 65.6 (59.23 to 71.93) | 69.9 (64.79 to 75.02) |
ELA is a numeric rating scale developed to characterize eyelash hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where 0=no eyelash, 1=minimal eyelash, 2=moderate eyelash and 3=normal eyelash. Higher scores represent lesser loss of eyelash hair.
| Percentage of participants | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) |
|---|---|---|
| Month 1 | 3.4 (1.34 to 5.53) | 37.7 (33.20 to 42.26) |
| Month 3 | 17.7 (13.27 to 22.19) | 42.5 (37.88 to 47.17) |
| Month 6 | 36.7 (31.03 to 42.36) | 47.1 (42.24 to 51.90) |
| Month 12 | 54.8 (48.63 to 60.97) | 56.5 (51.33 to 61.66) |
| Month 18 | 62.1 (55.93 to 68.33) | 61.2 (55.88 to 66.44) |
| Month 24 | 66.2 (59.90 to 72.51) | 68.1 (62.89 to 73.22) |
| Month 36 | 69.4 (62.73 to 75.98) | 70.5 (65.14 to 75.86) |
PGI-C is a self-administered single item questionnaire to evaluate the improvement or worsening of participant's AA as compared to the start of the study. Participants were required to select their response on a 7-point scale ranging from 1 (greatly worsened), 2=moderately worsened, 3=slightly worsened, 4=not changed, 5= slightly improved, 6=moderately improved, 7 (greatly improved). 95% CI was based on normal approximation.
| Percentage of participants | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) |
|---|---|---|
| Month 1 | 16.4 (12.97 to 19.91) | 55.2 (51.17 to 59.22) |
| Month 3 | 57.0 (52.34 to 61.74) | 59.3 (55.31 to 63.31) |
| Month 6 | 68.8 (64.38 to 73.21) | 66.4 (62.44 to 70.40) |
| Month 9 | 76.5 (72.34 to 80.69) | 69.5 (65.55 to 73.55) |
| Month 12 | 78.6 (74.55 to 82.74) | 72.6 (68.56 to 76.59) |
| Month 18 | 81.0 (76.88 to 85.03) | 74.8 (70.69 to 78.85) |
| Month 24 | 82.4 (78.31 to 86.47) | 78.6 (74.65 to 82.50) |
| Month 36 | 83.1 (78.77 to 87.33) | 79.0 (74.90 to 83.17) |
AAPPO scale is a 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over past week. Items 5-8 assessed emotional symptoms with responses scored from 0 ='never' to 4='always'. Items 9-11 assessed activity limitations with responses scored from 0='not at all' to 4='completely'. AAPPO emotional symptoms sub score was calculated as mean of items 5-8 and ranged from 0 (never) to 4 (always), where higher scores indicated more emotional symptoms. AAPPO activity limitations sub score was calculated as mean of items 9-11 and ranged from 0(not at all) to 4(completely), where higher scores indicated more activity limitations. For roll-over participants originating from Study B7931005 or B7981015, baseline is day 1 from Study B7931005 or B7981015. For de novo participants, baseline is day 1 from Study B7981032.
| Units on a scale | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) |
|---|---|---|
| Month 1: Emotional Symptoms | -0.33 ± 0.683 | -0.84 ± 1.036 |
| Month 3: Emotional Symptoms | -0.61 ± 0.867 | -0.86 ± 1.055 |
| Month 6: Emotional Symptoms | -0.77 ± 1.012 | -0.95 ± 1.087 |
| Month 9: Emotional Symptoms | -0.95 ± 1.091 | -0.95 ± 1.123 |
| Month 12: Emotional Symptoms | -1.00 ± 1.161 | -1.04 ± 1.128 |
| Month 18: Emotional Symptoms | -1.07 ± 1.174 | -1.11 ± 1.129 |
| Month 24: Emotional Symptoms | -1.12 ± 1.232 | -1.07 ± 1.172 |
| Month 36: Emotional Symptoms | -1.20 ± 1.246 | -1.11 ± 1.204 |
| Month 1: Activity Limitations | -0.09 ± 0.641 | -0.36 ± 0.789 |
| Month 3: Activity Limitations | -0.21 ± 0.667 | -0.38 ± 0.811 |
| Month 6: Activity Limitations | -0.27 ± 0.719 | -0.44 ± 0.829 |
| Month 9: Activity Limitations | -0.33 ± 0.781 | -0.45 ± 0.857 |
| Month 12: Activity Limitations | -0.36 ± 0.793 | -0.51 ± 0.871 |
| Month 18: Activity Limitations | -0.40 ± 0.830 | -0.51 ± 0.869 |
| Month 24: Activity Limitations | -0.43 ± 0.824 | -0.52 ± 0.890 |
| Month 36: Activity Limitations | -0.43 ± 0.858 | -0.53 ± 0.859 |
AAPPO scale is a 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over past week. Items 1-4 assessed current hair loss from the scalp, eyebrows, eyelashes and body using a 5 point scale that ranged from 0 ='no hair loss' and 4='complete hair loss'. In this outcome measure, percentage of participants with AAPPO domain scores of 0 = no hair loss or 1 = a little hair loss, among participants with score \>=2 at baseline are reported.
| Percentage of participants | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) |
|---|---|---|
| Month 1: Current hair loss on Scalp | 9.8 (6.96 to 12.66) | 37.2 (33.23 to 41.19) |
| Month 3: Current hair loss on Scalp | 27.5 (23.18 to 31.81) | 38.5 (34.43 to 42.49) |
| Month 6: Current hair loss on Scalp | 45.7 (40.89 to 50.55) | 46.4 (42.12 to 50.72) |
| Month 9: Current hair loss on Scalp | 55.6 (50.64 to 60.59) | 49.8 (45.37 to 54.22) |
| Month 12: Current hair loss on Scalp | 58.9 (53.91 to 63.93) | 52.7 (48.16 to 57.29) |
| Month 18: Current hair loss on Scalp | 62.2 (57.15 to 67.35) | 57.2 (52.52 to 61.97) |
| Month 24: Current hair loss on Scalp | 67.8 (62.72 to 72.86) | 60.7 (55.92 to 65.47) |
| Month 36: Current hair loss on Scalp | 69.3 (64.00 to 74.67) | 58.5 (53.34 to 63.61) |
| Month 1: Current hair loss on Eyebrows | 9.9 (6.33 to 13.38) | 42.9 (38.24 to 47.48) |
| Month 3: Current hair loss on Eyebrows | 32.4 (26.79 to 37.91) | 44.1 (39.43 to 48.79) |
| Month 6: Current hair loss on Eyebrows | 43.9 (37.94 to 49.80) | 49.5 (44.59 to 54.41) |
| Month 9: Current hair loss on Eyebrows | 49.0 (42.75 to 55.22) | 52.9 (47.88 to 57.97) |
| Month 12: Current hair loss on Eyebrows | 55.5 (49.17 to 61.85) | 55.0 (49.81 to 60.28) |
| Month 18: Current hair loss on Eyebrows | 60.9 (54.46 to 67.36) | 60.1 (54.77 to 65.48) |
| Month 24: Current hair loss on Eyebrows | 60.7 (53.94 to 67.45) | 64.4 (59.06 to 69.74) |
| Month 36: Current hair loss on Eyebrows | 63.8 (56.65 to 70.93) | 64.7 (59.08 to 70.37) |
| Month 1: Current hair loss on Eyelashes | 8.1 (4.60 to 11.57) | 40.9 (36.03 to 45.84) |
| Month 3: Current hair loss on Eyelashes | 35.8 (29.61 to 41.94) | 44.2 (39.22 to 49.20) |
| Month 6: Current hair loss on Eyelashes | 45.7 (39.21 to 52.09) | 46.6 (41.35 to 51.80) |
| Month 9: Current hair loss on Eyelashes | 54.2 (47.54 to 60.95) | 54.0 (48.57 to 59.36) |
| Month 12: Current hair loss on Eyelashes | 56.2 (49.36 to 63.08) | 55.3 (49.80 to 60.88) |
| Month 18: Current hair loss on Eyelashes | 61.9 (54.98 to 68.83) | 62.3 (56.61 to 67.94) |
| Month 24: Current hair loss on Eyelashes | 64.3 (57.15 to 71.51) | 65.0 (59.31 to 70.77) |
| Month 36: Current hair loss on Eyelashes | 69.8 (62.43 to 77.17) | 67.5 (61.55 to 73.47) |
| Month 1: Current hair loss on body | 14.7 (10.54 to 18.85) | 31.9 (27.51 to 36.25) |
| Month 3: Current hair loss on body | 24.3 (19.22 to 29.33) | 36.5 (31.96 to 41.06) |
| Month 6: Current hair loss on body | 34.6 (28.91 to 40.21) | 41.9 (37.06 to 46.78) |
| Month 9: Current hair loss on body | 43.7 (37.53 to 49.77) | 46.9 (41.82 to 51.98) |
| Month 12: Current hair loss on body | 52.3 (45.98 to 58.54) | 49.9 (44.60 to 55.12) |
| Month 18: Current hair loss on body | 55.9 (49.49 to 62.41) | 56.0 (50.52 to 61.43) |
| Month 24: Current hair loss on body | 59.1 (52.45 to 65.82) | 60.3 (54.75 to 65.78) |
| Month 36: Current hair loss on body | 65.2 (58.25 to 72.13) | 62.2 (56.44 to 68.01) |
HADS is a validated 14-item questionnaire used to assess states of anxiety and depression over the past week. The HADS consisted of 2 subscales, one for anxiety (HADS-A) and one for depression (HADS-D). The depression subscale comprised of 7 items with score ranging from 0 (no presence of depression) to 3 (severe feeling of depression). Total depression subscale score was calculated as the sum of 7 items and ranged from 0 to 21; higher score indicating greater severity of depression symptoms. For roll-over participants originating from Study B7931005 or B7981015, baseline is day 1 from Study B7931005 or B7981015. For de novo participants, baseline is day 1 from Study B7981032.
| Units on a scale | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) |
|---|---|---|
| Month 1 | -0.1 ± 2.27 | -0.6 ± 2.87 |
| Month 3 | -0.4 ± 2.47 | -0.5 ± 2.80 |
| Month 6 | -0.5 ± 2.60 | -0.7 ± 2.97 |
| Month 9 | -0.6 ± 2.64 | -0.9 ± 2.94 |
| Month 12 | -0.6 ± 2.66 | -0.9 ± 3.16 |
| Month 18 | -0.9 ± 2.72 | -0.9 ± 3.08 |
| Month 24 | -1.0 ± 2.75 | -1.1 ± 3.11 |
| Month 36 | -0.8 ± 2.92 | -1.0 ± 2.90 |
HADS is a validated 14-item questionnaire used to assess states of anxiety and depression over the past week. The HADS consisted of 2 subscales, one for anxiety (HADS-A) and one for depression (HADS-D). The anxiety subscale comprised of 7 items with score ranging from 0 (no anxiety) to 3 (severe anxiety). Total anxiety subscale score was calculated as the sum of 7 items and ranged from 0 to 21; higher score indicating greater severity of anxiety symptoms. For roll-over participants originating from Study B7931005 or B7981015, baseline is day 1 from Study B7931005 or B7981015. For de novo participants, baseline is day 1 from Study B7981032.
| Units on a scale | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) |
|---|---|---|
| Month 1 | -0.6 ± 2.57 | -0.9 ± 3.38 |
| Month 3 | -0.7 ± 2.65 | -0.9 ± 3.46 |
| Month 6 | -0.9 ± 2.79 | -1.2 ± 3.33 |
| Month 9 | -0.9 ± 3.02 | -1.1 ± 3.46 |
| Month 12 | -0.8 ± 3.14 | -1.1 ± 3.52 |
| Month 18 | -1.0 ± 3.01 | -1.1 ± 3.45 |
| Month 24 | -1.1 ± 3.21 | -1.2 ± 3.48 |
| Month 36 | -1.0 ± 3.35 | -1.1 ± 3.46 |
HADS is a validated 14-item questionnaire used to assess states of anxiety and depression over the past week. The HADS consisted of 2 subscales, one for anxiety (HADS-A) and one for depression (HADS-D). The depression subscale comprised of 7 items with score ranging from 0 (no presence of depression) to 3 (severe feeling of depression). Total depression subscale score was calculated as the sum of 7 items and ranged from 0 to 21; higher score indicating greater severity of depression symptoms. Improvement on HADS depression score was considered as achieving a "normal" depression subscale score indicative of an absence of depression. Among adults, a HADS-D score of 0-7 was considered "normal"; for adolescents, a HADS-D score of 0-6 was considered "normal". 95% CI was calculated based on normal approximation.
| Percentage of participants | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) |
|---|---|---|
| Month 1 | 53.1 (35.84 to 70.41) | 56.9 (44.15 to 69.64) |
| Month 3 | 63.3 (46.09 to 80.58) | 52.6 (39.67 to 65.59) |
| Month 6 | 70.0 (53.60 to 86.40) | 70.4 (58.19 to 82.55) |
| Month 9 | 65.5 (48.22 to 82.82) | 69.4 (56.48 to 82.29) |
| Month 12 | 58.6 (40.70 to 76.55) | 72.7 (59.57 to 85.89) |
| Month 18 | 84.6 (70.75 to 98.48) | 63.6 (49.42 to 77.85) |
| Month 24 | 83.3 (68.42 to 98.24) | 62.8 (48.34 to 77.24) |
| Month 36 | 80.0 (62.47 to 97.53) | 75.7 (61.85 to 89.50) |
HADS is a validated 14-item questionnaire used to assess states of anxiety and depression over the past week. The HADS consisted of 2 subscales, one for anxiety (HADS-A) and one for depression (HADS-D). The anxiety subscale comprised of 7 items with score ranging from 0 (no anxiety) to 3 (severe anxiety). Total anxiety subscale score was calculated as the sum of 7 items and ranged from 0 to 21; higher score indicating greater severity of anxiety symptoms. Improvement on HADS anxiety score was considered as achieving a "normal" anxiety subscale score indicative of an absence of anxiety. Among adults, a HADS-A score of 0-7 was considered "normal"; for adolescents, a HADS-A score of 0-8 was considered "normal". 95% CI was calculated based on normal approximation.
| Percentage of participants | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) |
|---|---|---|
| Month 1 | 51.1 (40.69 to 61.58) | 54.2 (45.25 to 63.23) |
| Month 3 | 46.5 (35.97 to 57.05) | 59.6 (50.64 to 68.65) |
| Month 6 | 53.6 (42.91 to 64.24) | 62.5 (53.53 to 71.47) |
| Month 9 | 50.0 (38.90 to 61.10) | 57.8 (48.53 to 67.07) |
| Month 12 | 54.4 (43.45 to 65.41) | 64.4 (55.22 to 73.62) |
| Month 18 | 69.9 (59.34 to 80.39) | 62.9 (53.27 to 72.50) |
| Month 24 | 73.1 (62.52 to 83.75) | 61.1 (51.25 to 70.86) |
| Month 36 | 62.1 (49.58 to 74.56) | 63.9 (53.52 to 74.19) |
Percentage of participants with anti-tetanus antibody level \>=1.0 IU/mL at Month 1 were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.
| Percentage of participants | Vaccine Sub-study: Tdap Vaccination |
|---|---|
| Vaccine Sub-study: Percentage of Participants With Anti-tetanus Antibody Level >=1.0 International Units Per Milliliter (IU/mL) at Month 1-Tdap Vaccination | 100 (79.4 to 100.0) |
Percentage of participants with anti-tetanus antibody level \>=0.1 IU/mL at Month 1 were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.
| Percentage of participants | Vaccine Sub-study: Tdap Vaccination |
|---|---|
| Vaccine Sub-study: Percentage of Participants With Anti-tetanus Antibody Level >=0.1 IU/mL at Month 1-Tdap Vaccination | 100 (79.4 to 100.0) |
Percentage of participants with \>=4 times increase in anti-tetanus antibody level from baseline were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.
| Percentage of participants | Vaccine Sub-study: Tdap Vaccination |
|---|---|
| Vaccine Sub-study: Percentage of Participants With >=4 Times Increase in Anti-tetanus Antibody Level From Baseline at Month 1-Tdap Vaccination | 50 (24.7 to 75.3) |
Geometric mean and 95% CI were calculated by exponentiating the mean logarithm of the observed data and the corresponding CIs. Fold change was defined as the ratio of the post-baseline result to the baseline result. The assay results below the LLOQ were set to 0.5 \* LLOQ except when pre-vaccination assay results is \< LLOQ while postvaccination result is \>= LLOQ, in which case the pre-vaccination value will be set to LLOQ.
| Fold change | Vaccine Sub-study: Tdap Vaccination |
|---|---|
| Vaccine Sub-study: Geometric Mean Fold Change in Anti-tetanus Levels Above Baseline Values at Month 1-Tdap Vaccination | 5.7 (3.1 to 10.6) |
Geometric mean and 95% CI were calculated by exponentiating the mean logarithm of the observed data and the corresponding CIs. Assay results below the LLOQ were set to 0.5\* LLOQ.
| milli-international units (mIU)/mL | Vaccine Sub-study: Tdap Vaccination |
|---|---|
| Vaccine Sub-study: Geometric Mean Concentrations (GMCs) of Anti-tetanus Antibody Levels at Month 1-Tdap Vaccination | 8.4 (5.8 to 12.1) |
Percentage of participants with hSBA titer \>=1.8 at 1 month post vaccination for serogroup C were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.
| Percentage of Participants | Vaccine Sub-study: Meningococcal ACWY Vaccination |
|---|---|
| Vaccine Sub-study: Percentage of Participants With Human Serum Bactericidal Activity (hSBA) Titer >=1:8 at Month 1 Post-vaccination for Serogroup C-Meningococcal ACWY Vaccination | 20 (0.5 to 71.6) |
Percentage of participants with hSBA titer \>=1.4 at 1 month post vaccination for serogroup C were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.
| Percentage of Participants | Vaccine Sub-study: Meningococcal ACWY Vaccination |
|---|---|
| Vaccine Sub-study: Percentage of Participants With hSBA Titer >=1:4 at Month 1 Post-vaccination for Serogroup C-Meningococcal ACWY Vaccination | 40 (5.3 to 85.3) |
Geometric mean and 95% CI were calculated by exponentiating the mean logarithm of the observed data and the corresponding CIs. Assay results below the LLOQ were set to 0.5\* LLOQ.
| Titers | Vaccine Sub-study: Meningococcal ACWY Vaccination |
|---|---|
| Baseline | 5.7 (3.6 to 8.8) |
| Month 1 | 14.1 (4.4 to 44.8) |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect; other important medical events.
| Participants | Vaccine Sub-study: Tdap Vaccination | Vaccine Sub-study: Meningococcal ACWY Vaccination |
|---|---|---|
| Vaccine Sub-study: Number of Participants With SAEs | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | Vaccine Sub-study: Tdap Vaccination | Vaccine Sub-study: Meningococcal ACWY Vaccination |
|---|---|---|
| Vaccine Sub-study: Number of Participants With AEs | 3 | 1 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs leading to discontinuation included participants who had an AE record that indicated that the AE caused the participant to be discontinued from the study or that action taken with study treatment was drug withdrawn.
| Participants | Vaccine Sub-study: Tdap Vaccination | Vaccine Sub-study: Meningococcal ACWY Vaccination |
|---|---|---|
| Vaccine Sub-study: Number of Participants With AEs Leading to Discontinuation | 0 | 0 |
Collected over Main Study: From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40). Vaccine Sub-study: From day of vaccination (Day 1) up to 35 days post last dose of vaccine (up to Day 36). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | 1/447 (0.2%) | 33/447 (7.4%) | 309/447 (69.1%) |
| Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | 1/603 (0.2%) | 43/603 (7.1%) | 372/603 (61.7%) |
| Vaccine Sub-study: Tdap Vaccination | 0/17 (0%) | 0/17 (0%) | 3/17 (17.6%) |
| Vaccine Sub-study: Meningococcal ACWY Vaccination | 0/13 (0%) | 0/13 (0%) | 1/13 (7.7%) |
| Event | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | Vaccine Sub-study: Tdap Vaccination | Vaccine Sub-study: Meningococcal ACWY Vaccination |
|---|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 3/447 | 0/603 | 0/17 | 0/13 |
| AppendicitisInfections and infestations | 1/447 | 4/603 | 0/17 | 0/13 |
| CholelithiasisHepatobiliary disorders | 0/447 | 2/603 | 0/17 | 0/13 |
| Anaphylactic reactionImmune system disorders | 0/447 | 2/603 | 0/17 | 0/13 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/447 | 2/603 | 0/17 | 0/13 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/447 | 2/603 | 0/17 | 0/13 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/447 | 2/603 | 0/17 | 0/13 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/447 | 2/603 | 0/17 | 0/13 |
| Myocardial infarctionCardiac disorders | 1/447 | 0/603 | 0/17 | 0/13 |
| Retinal artery occlusionEye disorders | 1/447 | 0/603 | 0/17 | 0/13 |
| Event | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | Vaccine Sub-study: Tdap Vaccination | Vaccine Sub-study: Meningococcal ACWY Vaccination |
|---|---|---|---|---|
| SARS-CoV-2 test positiveInvestigations | 108/447 | 127/603 | 0/17 | 0/13 |
| HeadacheNervous system disorders | 98/447 | 93/603 | 0/17 | 0/13 |
| COVID-19Infections and infestations | 55/447 | 99/603 | 0/17 | 0/13 |
| NasopharyngitisInfections and infestations | 62/447 | 65/603 | 0/17 | 0/13 |
| PyrexiaGeneral disorders | 59/447 | 64/603 | 0/17 | 0/13 |
| AcneSkin and subcutaneous tissue disorders | 57/447 | 38/603 | 0/17 | 0/13 |
| Upper respiratory tract infectionInfections and infestations | 56/447 | 73/603 | 0/17 | 0/13 |
| CoughRespiratory, thoracic and mediastinal disorders | 46/447 | 74/603 | 0/17 | 0/13 |
| FatigueGeneral disorders | 47/447 | 41/603 | 0/17 | 0/13 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 44/447 | 59/603 | 0/17 | 0/13 |
Full Analysis set comprised of all participants regardless of whether they received study intervention. Participants of main study and vaccine sub-study were not exclusive.
| Age, Customized(Participants) | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | Vaccine Sub-study: Tdap With or Without Meningococcal ACWY Vaccine | Total |
|---|---|---|---|---|
| Main Study — From 12 to <18 Years | 76 | 80 | — | 156 |
| Main Study — From 18 to <45 Years | 271 | 360 | — | 631 |
| Main Study — From 45 to <64 Years | 96 | 144 | — | 240 |
| Main Study — >=65 Years | 6 | 19 | — | 25 |
| Vaccine Substudy — From 12 to <18 Years | — | — | 0 | 0 |
| Vaccine Substudy — From 18 to <45 Years | — | — | 10 | 10 |
| Vaccine Substudy — From 45 to <64 Years | — | — | 7 | 7 |
| Vaccine Substudy — >=65 Years | — | — | 0 | 0 |
| Sex: Female, Male(Participants) | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | Vaccine Sub-study: Tdap With or Without Meningococcal ACWY Vaccine | Total |
|---|---|---|---|---|
| Main Study — Female | 289 | 375 | — | 664 |
| Main Study — Male | 160 | 228 | — | 388 |
| Vaccine Substudy — Female | — | — | 12 | 12 |
| Vaccine Substudy — Male | — | — | 5 | 5 |
| Ethnicity (NIH/OMB)(Participants) | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | Vaccine Sub-study: Tdap With or Without Meningococcal ACWY Vaccine | Total |
|---|---|---|---|---|
| Main Study — Hispanic or Latino | 55 | 76 | — | 131 |
| Main Study — Not Hispanic or Latino | 383 | 523 | — | 906 |
| Main Study — Unknown or Not Reported | 11 | 4 | — | 15 |
| Vaccine Substudy — Hispanic or Latino | — | — | 4 | 4 |
| Vaccine Substudy — Not Hispanic or Latino | — | — | 13 | 13 |
| Vaccine Substudy — Unknown or Not Reported | — | — | 0 | 0 |
| Race (NIH/OMB)(Participants) | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | Vaccine Sub-study: Tdap With or Without Meningococcal ACWY Vaccine | Total |
|---|---|---|---|---|
| Main Study — American Indian or Alaska Native | 5 | 3 | — | 8 |
| Main Study — Asian | 96 | 146 | — | 242 |
| Main Study — Native Hawaiian or Other Pacific Islander | 2 | 1 | — | 3 |
| Main Study — Black or African American | 16 | 21 | — | 37 |
| Main Study — White | 310 | 423 | — | 733 |
| Main Study — More than one race | 7 | 6 | — | 13 |
| Main Study — Unknown or Not Reported | 13 | 3 | — | 16 |
| Vaccine Substudy — American Indian or Alaska Native | — | — | 0 | 0 |
| Vaccine Substudy — Asian | — | — | 3 | 3 |
| Vaccine Substudy — Native Hawaiian or Other Pacific Islander | — | — | 0 | 0 |
| Vaccine Substudy — Black or African American | — | — | 1 | 1 |
| Vaccine Substudy — White | — | — | 13 | 13 |
| Vaccine Substudy — More than one race | — | — | 0 | 0 |
| Vaccine Substudy — Unknown or Not Reported | — | — | 0 | 0 |
Showing the first 100 of 144 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jul 2019 to primary completion in Jun 2024, 59 months.
Results were first posted in Aug 2025, 1 year 1 month after primary completion.
Of 20 phase 3 interventional studies under Alopecia Areata, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 46. This study's 59 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-06651600